AR126676A1 - GLP-1R AGONIST COMPOUND SALT, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF - Google Patents
GLP-1R AGONIST COMPOUND SALT, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOFInfo
- Publication number
- AR126676A1 AR126676A1 ARP220102061A ARP220102061A AR126676A1 AR 126676 A1 AR126676 A1 AR 126676A1 AR P220102061 A ARP220102061 A AR P220102061A AR P220102061 A ARP220102061 A AR P220102061A AR 126676 A1 AR126676 A1 AR 126676A1
- Authority
- AR
- Argentina
- Prior art keywords
- salt
- glp
- ammonium
- compounds
- agonist compound
- Prior art date
Links
- -1 GLP-1R AGONIST COMPOUND SALT Chemical class 0.000 title abstract 3
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 8
- 150000003863 ammonium salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 abstract 2
- UNIOAPGQAGSMOR-RTRLPJTCSA-N (3R,4R,5S,6R)-3-(dimethylamino)-6-(hydroxymethyl)oxane-2,4,5-triol Chemical class CN(C)[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O UNIOAPGQAGSMOR-RTRLPJTCSA-N 0.000 abstract 1
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical class CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 abstract 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical class CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 abstract 1
- HKLYDUXIXBVZOQ-UHFFFAOYSA-N 2-aminoethane-1,1,1-triol Chemical class NCC(O)(O)O HKLYDUXIXBVZOQ-UHFFFAOYSA-N 0.000 abstract 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical class OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 abstract 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 abstract 1
- WJHKHSVFLRPWMG-KEWYIRBNSA-N C(C)C1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO Chemical class C(C)C1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO WJHKHSVFLRPWMG-KEWYIRBNSA-N 0.000 abstract 1
- 239000004381 Choline salt Substances 0.000 abstract 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 abstract 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 1
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 abstract 1
- 125000002066 L-histidyl group Chemical class [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 108010077895 Sarcosine Proteins 0.000 abstract 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 abstract 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 abstract 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 235000019417 choline salt Nutrition 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 abstract 1
- 150000005332 diethylamines Chemical class 0.000 abstract 1
- 150000004656 dimethylamines Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002169 ethanolamines Chemical class 0.000 abstract 1
- 150000003947 ethylamines Chemical class 0.000 abstract 1
- 150000002301 glucosamine derivatives Chemical class 0.000 abstract 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical class NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 150000002505 iron Chemical class 0.000 abstract 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical class CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 abstract 1
- 229910003002 lithium salt Inorganic materials 0.000 abstract 1
- 159000000002 lithium salts Chemical class 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 150000003956 methylamines Chemical class 0.000 abstract 1
- 150000002780 morpholines Chemical class 0.000 abstract 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical class ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 abstract 1
- 150000004885 piperazines Chemical class 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- 229940043230 sarcosine Drugs 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical class CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 abstract 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 abstract 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 abstract 1
- 150000003751 zinc Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención pertenece al campo técnico de los medicamentos químicos y provee una serie de sales de compuestos agonistas de GLP-1R. La presente invención también se relaciona con composiciones farmacéuticas que comprenden las sales de estos compuestos y con el uso de los compuestos en medicamentos para el tratamiento de enfermedades tales como la diabetes, etc. Reivindicación 1: Una sal de compuesto agonista de GLP-1R como se muestra en la fórmula (1), caracterizada porque: n es de 0,3 hasta 3; M y el carboxilo forman una sal, y la sal se selecciona de por lo menos una de sal de litio, sal de sodio, sal de potasio, sal de calcio, sal de magnesio, sal de aluminio, sal de hierro, sal de zinc o sal de amonio; o la sal se selecciona de por lo menos una de sal de metilamina, sal de dimetilamina, sal de trimetilamina, sal de etilamina, sal de dietilamina, sal de trietilamina, sal de isopropilamina, sal de 2-etilaminoetanol, sal de piridina, sal de metilpiridina, sal de etanolamina, sal de dietanolamina, sal de amonio, sal de tetrametil amonio, sal de tetraetil amonio, sal de trietanolamina, sal de piperidina, sal de piperazina, sal de morfolina, sal de lisina, sal de L-lisina, sal de arginina, sal de L-arginina, sal de histidina, sal de L-histidina, sal de meglumina, sal de dimetilglucosamina, sal de etilglucosamina, sal de diciclohexilamina, sal de 1,6-hexanodiamina, sal de glucosamina, sal de sarcosina, sal de serinol, sal de trihidroximetil aminometano, sal de aminopropanodiol, sal de ornitina o sal de colina. Reivindicación 9: Una composición farmacéutica, que comprende la sal de compuesto agonista de GLP-1R de acuerdo con cualquiera de las reivindicaciones 1 a 8, y más de un portador aceptable farmacéuticamente.The present invention belongs to the technical field of chemical medicines and provides a series of salts of GLP-1R agonist compounds. The present invention also relates to pharmaceutical compositions comprising the salts of these compounds and to the use of the compounds in medicaments for the treatment of diseases such as diabetes, etc. Claim 1: A salt of GLP-1R agonist compound as shown in formula (1), characterized in that: n is 0.3 to 3; M and the carboxyl form a salt, and the salt is selected from at least one of lithium salt, sodium salt, potassium salt, calcium salt, magnesium salt, aluminum salt, iron salt, zinc salt or ammonium salt; or the salt is selected from at least one of methylamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylamine salt, triethylamine salt, isopropylamine salt, 2-ethylaminoethanol salt, pyridine salt, salt methylpyridine, ethanolamine salt, diethanolamine salt, ammonium salt, tetramethyl ammonium salt, tetraethyl ammonium salt, triethanolamine salt, piperidine salt, piperazine salt, morpholine salt, lysine salt, L-lysine salt , arginine salt, L-arginine salt, histidine salt, L-histidine salt, meglumine salt, dimethylglucosamine salt, ethylglucosamine salt, dicyclohexylamine salt, 1,6-hexanediamine salt, glucosamine salt, salt of sarcosine, serinol salt, trihydroxymethyl aminomethane salt, aminopropanediol salt, ornithine salt or choline salt. Claim 9: A pharmaceutical composition, comprising the GLP-1R agonist compound salt according to any of claims 1 to 8, and more than one pharmaceutically acceptable carrier.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110879439 | 2021-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126676A1 true AR126676A1 (en) | 2023-11-01 |
Family
ID=85154423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102061A AR126676A1 (en) | 2021-08-02 | 2022-08-02 | GLP-1R AGONIST COMPOUND SALT, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN117693504A (en) |
| AR (1) | AR126676A1 (en) |
| TW (1) | TW202321240A (en) |
| WO (1) | WO2023011395A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20191501A1 (en) * | 2016-12-16 | 2019-10-22 | Pfizer | GLP-1 RECEPTOR AGONISTS AND THEIR USES OF THE SAME |
| CN112566637B (en) * | 2018-06-15 | 2023-11-14 | 辉瑞公司 | GLP-1 receptor agonists and uses thereof |
| WO2021018023A1 (en) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | Small molecule glp-1 receptor modulator |
| CN115461334A (en) * | 2020-11-27 | 2022-12-09 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative and preparation method and medical application thereof |
-
2022
- 2022-08-01 TW TW111128703A patent/TW202321240A/en unknown
- 2022-08-01 WO PCT/CN2022/109367 patent/WO2023011395A1/en active Application Filing
- 2022-08-01 CN CN202280051627.2A patent/CN117693504A/en active Pending
- 2022-08-02 AR ARP220102061A patent/AR126676A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117693504A (en) | 2024-03-12 |
| WO2023011395A1 (en) | 2023-02-09 |
| TW202321240A (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021000537A2 (en) | Inflammasome nlrp3 inhibitors | |
| UY31046A1 (en) | SUBSTITUTED DERIVATIVES OF N- (3,4-DIHIDRO-2H-CROMEN-3-IL) FORMAMIDA AND N- (1, 2,3, 4-TETRAHIDRONAFTALEN-2-IL) FORMAMIDA, SALTS OF THE SAME, COMPOSITIONS THAT CONTAIN THEM , PROCEDURES FOR PREPARATION AND APPLICATIONS | |
| BRPI0908353B8 (en) | compound or a pharmaceutically acceptable salt thereof and pharmaceutical composition | |
| UY38602A (en) | CONDENSED TRICYCLIC COMPOUNDS | |
| RU2016135952A (en) | DOPA-DECARBOXYLASE INHIBITOR COMPOSITIONS | |
| BR122021005860A8 (en) | DERIVATIVES OF AMINO ACIDS AND COMPOSITION INCLUDING THEM | |
| BR112015014222A2 (en) | compound, pharmaceutical composition, use of a compound, method for treating anemia and pharmaceutical composition | |
| BR112016028876A2 (en) | compound, pharmaceutical composition, method for treating a disease or condition in a human, kit, and use of a compound, a salt, isomer or a pharmaceutically acceptable mixture thereof. | |
| BR112022007577A2 (en) | DERIVATIVES OF [(1,5-DIPHENYL-1H-1,2,4-TRIAZOLE-3-YL)OXY]ACETIC ACID AND SALTS THEREOF, COMPOSITIONS FOR PROTECTING CROPS INCLUDING THEM, METHODS FOR PRODUCING THEM AND USE OF THE SAME FOR PROTECTIVE AGENTS | |
| BR112015020639A2 (en) | glyphosate composition for dicamba tank mixtures with enhanced volatility | |
| CO6290625A2 (en) | COMPOSITIONS CONTAINING BASIC AMINO ACID AND SOLUBLE CARBONATE SALT FORMED IN SITU | |
| BR112016028642A2 (en) | compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof. | |
| RU2011102291A (en) | APPLICATION OF CATIONIC SURFACTANTS AS SPORICID AGENTS | |
| JP2017507973A5 (en) | ||
| BR112017015958A2 (en) | transdermally absorbable base material containing lipid-peptide compound | |
| RU2007136782A (en) | HIV INHIBITING 2- (4-CYANOPHENYL) -6-HYDROXYLAMINOPYRIMIDINES | |
| BR112023003832A2 (en) | INNOVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | |
| MA38854B1 (en) | Amide derivatives used as lysophosphatidic acid receptor antagonists | |
| EA200401108A1 (en) | SALT TOLTERODINE | |
| AR126676A1 (en) | GLP-1R AGONIST COMPOUND SALT, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | |
| Starodubtseva et al. | Design, synthesis, and biological activity of novel ammonium salts containing sterically hindered phenolic fragment and phosphoryl group | |
| AR075097A1 (en) | CRYSTAL POLYMAL SALES AND FORMS OF [4- (6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-IL) -PENYL] -5-CHLORINE-THIOPHEN-2- IL-SULFONIL UREA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD TO PREPARE THEM AND USE OF THE SAME IN THE TREATMENT OF CARDIOVASCULAR DISEASES ASSOCIATE | |
| BR0206730A (en) | Process for preparing a non-hygroscopic sodium valproate composition, a non-hygroscopic pharmaceutical composition and its use | |
| CO2024002844A2 (en) | Spirocyclic compounds | |
| BR112022002772A2 (en) | CRYSTALLINE FORMS OF QUINOLINE ANALOGS AND SALTS THEREOF, COMPOSITIONS AND THEIR METHODS FOR USE |